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Pseudomonas aeruginosa (Pa) is the predominant 
pulmonary pathogen in adult patients with cystic 
fibrosis (CF), a chronic progressive disease of 
which the primary cause of death is respiratory fail-
ure resulting from chronic pulmonary inflamma-
tion and infection.1 The presence of Pa is an 
unfavourable prognostic indicator and is associ-
ated with accelerated lung tissue destruction and 
decline in lung function, leading to increased mor-
bidity and mortality.2–4 In Europe more than half 
of the adult CF patients have a chronic Pa infec-
tion.5 Once chronic infection is established, Pa is 
virtually impossible to eradicate. However, early 
infections with Pa usually have a low bacterial 
load, offering an opportunity for eradication.6–9
Different eradication strategies are available, 
including tobramycin or colistin inhalation or 
intravenous administration, sometimes combined 
with oral ciprofloxacin.10,11 The advantage of 
inhaled antibiotics consists of facilitating high 
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Abstract
Background: Pseudomonas aeruginosa (Pa) is the predominant pulmonary pathogen in patients 
with cystic fibrosis (CF). Tobramycin nebulization is used for the eradication of Pa infection. 
Nowadays, tobramycin dry powder inhalation (DPI) is available as well. This study reports the 
results of eradicating Pa with tobramycin DPI versus nebulization.
Methods: Adult CF patients with a Pa isolation between September 2010 and September 2017 
from the University Medical Centre Groningen (UMCG), the Netherlands, were included in this 
retrospective study.
Results: In total 27 Pa isolations were recorded. In 13 of these, eradication was attempted 
with tobramycin, 7 with DPI and 6 with nebulization. DPI eradicated Pa successfully in six 
isolations (85.7%). Of these, one patient received additional oral ciprofloxacin and one received 
intravenous ceftazidime. Nebulization eradicated three Pa isolations (50.0%), in two of these, 
additional oral ciprofloxacin was given.
Conclusion: Eradication rates of DPI tobramycin are comparable with those for nebulized 
tobramycin reported in the literature. This study suggests that DPI tobramycin is an 
alternative to nebulized tobramycin for eradication of Pa.
Trial registration: The Medical Ethics Committee of the UMCG granted a waiver (METC2017-
349), as they concluded that this study was not subject to the Medical Research Involving 
Human Subjects Act.
The reviews of this paper are available via the supplemental material section.
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drug concentrations at the target site in the lung, 
while minimizing systemic exposure and toxicity. 
The most frequently applied method of adminis-
tration for inhaled antibiotics is by wet nebuliza-
tion. Nowadays, dry powder inhalation of a few 
antibiotics is available in Europe since September 
2010.12–14 Hypothetically, these dry powder anti-
biotics have several advantages over nebulization: 
more effective lung deposition, reduced adminis-
tration time and lower risk of auto-re-infection 
when used with a disposable inhaler. In daily 
practice, these dry powder antibiotics are now 
used to eradicate Pa infections. To the best of the 
authors knowledge, whether these dry powder 
antibiotics are equally effective in eradicating Pa 
compared with administration through nebuliza-
tion has not been studied previously.
This study compares the results of eradicating Pa 
with dry powder tobramycin (DPI tobramycin) 
with nebulized tobramycin from our own experi-
ence and in comparison with reported results 
from the literature.
Methods
This was a retrospective study from September 
2010 until September 2017 concerning adult CF 
patients from the CF centre University Medical 
Centre Groningen (UMCG) in the Netherlands. 
Inclusion and exclusion criteria are listed in 
Table 1. We focused on incident Pa cases; thus, 
patients were included more than once when they 
had more than one Pa infection during the study 
period if they were declared free from Pa accord-
ing to the Leeds criteria. Patients treated with 
DPI tobramycin received 112 mg twice daily for 
28 days, for tobramycin nebulization dosage con-
sisted of 300 mg twice daily for 28 days. The 
Medical Ethics Committee of the UMCG granted 
a waiver (METC2017-349), as they concluded 
that this study was not subject to the Medical 
Research Involving Human Subjects Act.
The primary outcome was the eradication of the 
Pa infection, defined as at least three Pa negative 
sputum cultures over 6 months. Secondary out-
come parameters were time to recurrence of Pa 
after successful eradication, and development of 
chronic Pa infection.
Results
All 113 adult CF patients were assessed for eligi-
bility. Of these, 69 (61.1%) were excluded. 
Reasons for exclusion were chronic Pa (53; 
76.8%), lung transplantation before start of study 
(15; 21.7%) and one person had no sputum cul-
tures taken due to mild CF (1.5%). Of the 44 
included patients, 18 (40.9%) were found to have 
one or more Pa infection during the study period. 
In total 27 incident Pa isolations were recorded. 
A total of 14 were excluded due to receiving treat-
ment other than tobramycin inhalation; too many 
missing data (in three patients too few sputum 
cultures were available after treatment); or not 
meeting Leeds criteria for early/new Pa isolation 
(two patients). In the end, 13 Pa isolations were 
found eligible for analysis, of which 7 were treated 
with DPI tobramycin, and 6 with tobramycin 
nebulization. Treatment with DPI tobramycin 
consisted of 112 mg twice daily for 28 days 
(Podhaler®). Patients treated with tobramycin 
nebulization received 300 mg twice daily for 
Table 1. Inclusion and exclusion criteria.
Inclusion criteria -  Patients diagnosed with CF with clinical signs consistent with CF and sweat chloride 
>60 mEq/l or two CF-causing mutations identified
-  An initial or new Pa isolation from sputum cultures during the study period, treated 
with tobramycin nebulization or tobramycin dry powder (DPI tobramycin)*
-  Multiple sputum cultures after the end of treatment
Exclusion criteria -  Chronic Pa infection
-  Patients receiving Pa suppressing therapy
-  Lung transplantation before Pa isolation
-  Incomplete exposure and/or outcome data
*Pa isolation was defined as initial Pa isolation when the patient hadn’t been infected with Pa prior to this Pa isolation. 
For new Pa isolation, patients had to be free of Pa, defined by the Leeds criteria, whereby all cultures taken in the last 
12 months prior to Pa isolation had to be Pa negative.
CF, cystic fibrosis; DPI, dry powder inhalation; Pa, Pseudomonas aeruginosa.
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Table 2. Clinical characteristics.
Dry powder 
tobramycin (n = 7)
Nebulization 
tobramycin (n = 6)
Gender, n (%)
 Male 3 (42.9) 1 (16.7)
 Female 4 (57.1) 5 (83.3)
Age in years, mean (range) 33.8 (23.8–51.5) 28.4 (18.6–39.3)
BMI, mean (range) 24.7 (20.8–29.5) 21.7 (16.6–29.1)
CFTR mutation, n (%)
 Homozygote_Phe508del 6 (85.7) 4 (66.7)
 Heterozygote_Phe508del – 2 (33.3)
 Other 1 (14.3) –
 Unknown – –
Comorbidities, n (%)
 Cystic fibrosis-related diabetes 2 (28.6) 3 (50.0)
 Cystic fibrosis-related liver disease 1 (14.3) 2 (33.3)
 Pancreas insufficiency 7 (100.0) 5 (83.3)
 Osteoporosis 1 (14.3) 1 (16.7)
Forced Expiratory Volume in 1 second
 Percentage of predicted, mean (range, ±SD) 80.7 (58–100, ±18.5) 78.8 (29–106, ±33.5)
 Absolute, mean (range, ±SD) 2.9 (1.88–4.1, ±0.8) 2.9 (0.99–4.76, ±1.4)
Pa infection new/first 4/3 6/0
Coinfection with pathogens, n (%)
 Staphylococcus aureus 7 (100.0) 4 (66.7)
 Haemophilus influenza 2 (28.6) 2 (33.3)
 Streptococcus pneumoniae 0 0
 Aspergillus 5 (71.4) 4 (66.7)
 Acinetobacter 2 (28.6) 0
 Stenotrophomonas maltophilia 0 1 (16.7)
 Burkhholderia 0 0
 Nontuberculosis Mycobacteria 0 0
BMI, body mass index; CFTR, Cystic fibrosis transmembrane conductance regulator; Pa, Pseudomonas aeruginosa;  
SD, standard deviation. 
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28 days. Different nebulizers were used by the 
various patients. Table 2 liststhe clinical charac-
teristics of the 13 Pa infections.
Of the seven Pa isolations treated with DPI 
tobramycin, eradication was successful in six 
cases (85.7%), however in one case only two spu-
tum cultures were available in the year after treat-
ment instead of three. In only one case, Pa 
infection was not eradicated with DPI tobramy-
cin. In five of the seven isolations, DPI tobramy-
cin was used without comedication. In one of the 
six eradicated cases, oral ciprofloxacin (20 mg/kg 
twice daily, with a maximum total dosage of 
1500 mg per day for 2 weeks) was added to DPI 
tobramycin; in one case, DPI was combined with 
intravenous ceftazidime (in a dosage of 8 gram/24 h, 
for 14 days).
In the group with nebulized tobramycin, eradica-
tion was achieved in three out of six cases (50.0%); 
in two of them, tobramycin nebulization was 
combined with oral ciprofloxacin. Statistical anal-
ysis using Fisher’s exact test showed no signifi-
cant difference in eradication rate between 
treatment with DPI and nebulization (p = 0.266).
Mean time to reinfection or end of study for those 
without recurrence during the study period in the 
group treated with DPI tobramycin was 552.8 days 
versus 123.0 days in the nebulization group. The 
log-rank test showed a significant difference 
(p = 0.018). No patients treated with DPI tobramy-
cin developed chronic infection versus two patients 
in the nebulization group. Fisher’s exact test 
showed no significant difference (p = 0.192).
Discussion
Treatment with DPI tobramycin appears to be 
at least as effective as nebulization in achieving 
Pa eradication, since 85.8% of Pa was eradi-
cated with DPI compared with 50.0% with 
 nebulization. In the literature, numbers of erad-
ication success from nebulized tobramycin vary 
widely.15 Gibson found an overall eradication 
efficacy of 74%, evaluated 1–3 months after 
ending treatment.16 In the first ever Pa isola-
tions, 14 out of 15 persons (93%) remained free 
of Pa after 1 year of treatment with tobramycin 
nebulization.17 Proesmans found an eradication 
success of 79.3%, evaluated at the end of treat-
ment with nebulized tobramycin for 28 days. At 
1 year follow-up, 44.8% were still free of Pa.18 A 
study by Taccetti recorded an eradication suc-
cess of 65% with nebulized tobramycin for 
28 days combined with oral ciprofloxacin, eradi-
cation defined as three negative cultures over 
6 months.19
The lower eradication success by nebulization of 
50% in our study may be owing to the fact that 
only adults were included in contrast with most 
other studies, causing the presence of not only 
first Pa isolations but also new Pa isolations. The 
acquisition of Pa at an older age negatively affects 
eradication success.9 For DPI tobramycin, we 
showed that its success rate of 85.7% is compara-
ble with the numbers reported in the literature. 
As soon as treatment success is similar, other ben-
efits such as ease of use, time burden and con-
venience become more important.
The main limitation of this study was the small 
population size, preventing us from drawing firm 
conclusions. Furthermore, it prevented us from 
performing statistical analyses corrected for con-
founding factors, such as forced expiratory vol-
ume in 1 second and body mass index, to reflect 
health status. Moreover, administration of either 
DPI tobramycin or nebulization was not rand-
omized. However, looking at the characteristics 
of the 13 incident Pa infections, the clinical con-
dition of the patients treated with DPI tobramy-
cin seems to be similar to those treated with 
nebulized tobramycin.
In conclusion, the present study suggests that 
DPI tobramycin might be a good alternative to 
nebulized tobramycin for the eradication of Pa. 
Further research is needed to evaluate DPI 
tobramycin as an eradication strategy, as it can 
potentially increase treatment effectiveness and 
patient convenience, ultimately improving clini-
cal outcome.
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